

Media Release, April 13, 2016

## **BB Biotech AG with after-tax loss in the first quarter of 2016**

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first quarter of 2016.

Based on preliminary unaudited consolidated results, BB Biotech AG closed the first quarter of 2016 with a loss of CHF 1.2 billion (CHF 379 million profit in the corresponding period of the previous year). As an investment company, the results reflect the performance of the stocks it holds in its investment portfolio.

The net income figure for the first quarter of 2016 reflects the overall difficult start into 2016 for equity markets. The accelerated profit-taking in the biotechnology sector was driven by many years of outperformance and the continued debate over healthcare affordability and drug prices in the context of the US presidential election campaigns. As a result, valuations in the sector are particularly attractive and for large caps at a decade low.

BB Biotech's share price decreased 16.5% in CHF and 17.4% in EUR during the corresponding period.

The interim report as of March 31, 2016 will be published on April 22, 2016.

### **For further information:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Tanja Chicherio, Tel. +41 44 267 67 07, [tch@bellevue.ch](mailto:tch@bellevue.ch)

**[www.bbbiotech.com](http://www.bbbiotech.com)**

### **Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.